ご寄付はこちら

論文

21. JACCRO GC-06

UPDATE : 2017/10/10

Multicenter phase II study of trastuzumab plus S 1 alone in elderly patients with HER2 positive advanced gastric cancer (JACCRO GC-06)
Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, Kazuhiro Nishikawa, Chikara Kunisaki, Satoshi Matsusaka, Yoshihiko Segawa, Masato Nakamura, Kinro Sasaki, Narutoshi Nagao, Yukimasa Hatachi, Yasuhiko Yuasa, Shinya Asami, Masahiro Takeuchi, Hiroshi Furukawa, Toshifusa Nakajima on behalf of the JACCRO GC-06 Study Group
Gastric Cancer
DOI 10.1007/s10120-017-0766-x

20. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/09/15

CEA response and depth of response (DpR) to predict clinical utcomes of first-line cetuximab treatment for metastatic colorectal cancer
Y. Sunakawa, A. Tsuji, T. Denda, Y. Segawa, Y. Negoro, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka, H. Tanioka, A. Takagane, S. Tani, T. Yamaguchi, T. Watanabe, M. Takeuchi, M. Fuji, W. Ichikawa
Targeted Oncology

19. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/05/19

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
Annals of Oncology 2017; 28 (8): 2030?31
Y. Sunakawa, A. Tsuji, M. Fujii, W. Ichikawa
DOI: https://doi.org/10.1093/annonc/mdx231

18. JACCRO CC-05、JACCRO CC-06

UPDATE : 2016/10/12

Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials.
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
Clinical Colorectal Cancer 2017; 16(3): e171-180
DOI: http://dx.doi.org/10.1016/j.clcc.2016.09.010

17. JACCRO CC-05/CC-06AR

UPDATE : 2016/10/12

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
A Sebio, S Stintzing, V Heinemann, Y Sunakawa, W Zhang, W Ichikawa, A Tsuji, T Takahashi, A Parek, D Yang, S Cao, Y Ning, S Stremitzer, S Matsusaka, S Okazaki, A Barzi, M D Berger and H-J Lenz.
The Pharmacogenomics Journal
DOI:10.1038/tpj.2016.69

16. JACCRO CC-05

UPDATE : 2016/06/20

Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05)
A. Tsuji, Y. Sunakawa, W. Ichikawa, M. Nakamura, M. Kochi, T. Denda, T. Yamaguchi, K. Shimada, A. Takagane, S. Tani, M. Kotaka, H. Kuramochi, K. Furushima, J. Koike, Y. Yonemura, M. Takeuchi, M. Fujii, T. Nakajima.
Targeted Oncology 2016; 11(6): 799-806
DOI: 10.1007/s11523-016-0445-6

15. JACCRO CC-05/CC-06AR

UPDATE : 2016/06/20

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Y. Sunakawa, D. Yang, M. Moran, S. H. Astrow, A. Tsuji, C. Stephens, W. Zhang, S. Cao, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka,Y. Segawa, T. Masuishi, M. Takeuchi, M. Fujii, T. Nakajima, W. Ichikawa, H. Lenz.
Cancer Biology & Therapy 2016: 17(7): 751-9
DOI:10.1080/15384047.2016.1178426

14. JACCRO GC-04

UPDATE : 2016/04/21

Exploratory phase II trial in a multicenter setting to evaluate the clinical value of chemosensitivity test in patients with gastric cancer (JACCRO GC-04, Kubota memorial trial)
N. Tanigawa, H. Yamaue, S. Ohyama, S. Sakuramoto, T. Inada, Y. Kodera, Y. Kitagawa, K. Omura, M. Terashima, Y. Sakata, A. Nashimoto, T. Yamaguchi, K. Chin, E. Nomura, S.W. Lee, M. Takeuchi, M. Fujii, T. Nakajima
Gastric Cancer 2016; 19(2): 350-60
DOI 10.1007/s10120-015-0506-z

13. JACCRO GY-01

UPDATE : 2016/02/09

Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
K. Umayahara, M. Takekuma, Y. Hirashima, S. Noda, T. Ohno, E. Miyagi, F. Hirahara, E. Hirata, E. Kondo, T. Tabata, Y. Nagai, Y. Aoki, M. Wakatsuki, M. Takeuchi, T. Toita, N. Takeshima, K. Takizawa
Gynecol Oncol 2016; 140 (2): 253-258
Doi: 10.1016/j.ygyno.2015.12.008

12. JACCRO CC-04

UPDATE : 2015/11/10

A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
S. Matsusaka, S. Ishihara, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shimbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima, T. Watanabe.
Radiother Oncol. 2015 Aug;116(2):209-13. 
doi: 10.1016/j.radonc.2015.08.002.

11. JACCRO GC-05

UPDATE : 2015/11/10

Phase II/III study of second-line chemotherapy comparing irinotecan alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
K. Tanabe, M. Fujii, K. Nishikawa, C. Kunisaki, A. Tsuji, N. Matsuhashi, A. Takagane, T. Ohno, T. Kawase, M. Kochi, K. Yoshida, Y. Kakeji, W. Ichikawa, K. Chin, M. Terashima, M. Takeuchi and T. Nakajima on behalf of the JACCRO GC-05 study group.
Ann Oncol (2015) 26 (9): 1916-1922
Doi: 10.1093/annonc/mdv265

10. JACCRO CC-04

UPDATE : 2015/11/10

A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
S. Ishihara, S. Matsusaka, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shinbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima and T. Watanabe. 
Radiation Oncology (2015) 10:24 
DOI 10.1186/s13014-015-0333-8

9. JACCRO GC-03

UPDATE : 2015/11/10

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
W. Koizumi, Y. H. Kim, M. Fujii, H. K. Kim, H. Imamura, K. H. Lee, T. Hara, H. C. Chung, T. Satoh, J. Y. Cho, H. Hosaka, A. Tsuji, A. Takagane, M. Inokuchi, K. Tanabe, T. Okuno, M. Ogura, K. Yoshida, M. Takeuchi, T. Nakajima; JACCRO and KCSG Study Group.
J Cancer Res Clin Oncol 2014; 140: 319-28
doi: 10.1007/s00432-013-1563-5

8. JACCRO CC-03

UPDATE : 2013/12/01

FOLFIRI plus bevacizumab as a first-line treatment for Japanese
patients with metastatic colorectal cancer: a JACCRO CC-03
multicenter phase II study.
M. Kochi, Y. Akiyama, T. Aoki, K. Hagiwara, T. Takahashi, K. Hironaka, F. Teranishi, F. Osuka, M. Takeuchi, M. Fujii, T. Nakajima.
Cancer Chemother Pharmacol 2013; 72, 1097-102
doi: 10.1007/s00280-013-2292-9

7. JACCRO PC-01

UPDATE : 2012/06/07

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T. Cancer Chemother Pharmacol 2012; 69 : 1197-204.

6. JACCRO LC-01

UPDATE : 2011/09/01

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study) ; Imamura, F. , Nishio, M. , Noro, R. , Tsuboi, M., Ikeda, N. Inoue, A. , Ohsaki, Y. , Kimura, Y. , Nishino, K., Uchida, J., Horai, T. : Chemotherapy 2011;57:357-362

5. 統計学の基礎知識と解析ソフト

UPDATE : 2011/09/01

がん研有明病院 中島 聰總、防衛医科大学校 佐藤弘樹, 
Drug Delivery System Vol.26 No2, 148-154(2011)

4. 日本がん臨床試験推進機構(JACCRO)の紹介

UPDATE : 2011/09/01

日本がん臨床試験推進機構(JACCRO);中島 聰總、山口 俊晴、藤井 雅志、島田 安博、竹内 正弘, 腫瘍内科 Vol.6 No.4, 305-311(2010)

3. JACCRO CC-02

UPDATE : 2011/09/01

Phase II study of FOLFOX4 with “wait and go” strategy as Wrst-line treatment for metastatic colorectal cancer;Mitsugu Kochi ? Wataru Ichikawa ? Eiji Meguro ? Hiroyuki Shibata ? Takuji Fukui ?Michitaka Nagase ? Yutaka Hoshino ? Masahiro Takeuchi ? Masashi Fujii ? Toshifusa Nakajima. Cancer Chemother Pharmacol 2011;68:1215-1222

2. JACCRO GC-01

UPDATE : 2011/09/01

A phaseⅡ study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for serosa-positive gastric cancer (JACCRO GC-01 study);T.Yoshikawa, K.Omura, O.Kobayashi, A.Nashimoto, A.Takabayashi, T.Yamada, H.Yamaue, M.Fujii, T.Yamaguchi, T.Nakajima.. Europian J Surg Oncol 2010 ; 36 : 546-551 (2010).

1. FLADS systemの紹介

UPDATE : 2011/09/01

FLADS systemの紹介抗癌剤開発臨床試験へのJACCROの取り組み - FLADS(Flexible License Assisted Data Server)systemによるsupport - ; 中島聰總、山口俊晴、藤井雅志、島田安博、福井巌、曽根三郎、鶴尾隆、竹内正弘、小川一誠、青柳宏. 外科治療 Vol.97 No.5, 517-523(2007)